Suppr超能文献

用于胸腹主动脉瘤(TAA)修复的定制装置(CMD):新加坡一家东南亚单一中心的中长期结果

Custom-Made Device (CMD) for the Repair of Thoraco-Abdominal Aneurysm (TAA): Mid-Long Term Outcomes from a Single Southeast Asian Centre Experience in Singapore.

作者信息

Ng Nick Zhi Peng, Pang Jolyn Hui Qing, Yap Charyl Jia Qi, Chao Victor Tar Toong, Tay Kiang Hiong, Chong Tze Tec

机构信息

Department of Vascular Surgery, Singapore General Hospital, Outram Road, Singapore 169856, Singapore.

Department of Cardiothoracic Surgery, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609, Singapore.

出版信息

J Clin Med. 2024 Oct 15;13(20):6145. doi: 10.3390/jcm13206145.

Abstract

Given the high risk of peri-operative morbidity and mortality associated with open repair, endovascular repair for thoraco-abdominal aneurysms is increasingly performed. This study aims to describe mid to long-term results for patients who were treated with COOK Custom-Made Endograft Device at a single Southeast Asian tertiary centre. Mid to long-term results of patients treated from 2012 to 2022 were retrospectively reviewed. Indications for treatment were aortic diameter > 5.5 cm, enlargement > 5 mm in 6 months or high-risk morphology. Clinical, operative, early to late complications and reintervention details were captured. The endpoints were technical success, primary patency and primary assisted patency. Electronic medical records of 29 consecutive patients (64.4 ± 1.6 years old; 26/29 males 89.6%) were reviewed. 24/29 (83%) were hypertensive, and 20/29 (69%) were smokers. The mean diameter was 5.5 cm, and the majority were treated for Crawford type IV (19/29, 65.5%). Endograft deployment was 100%. Catheterisation of fenestration was successful in 109/116 (94%). 30-day mortality and morbidity were observed in 12/29 (41%), for which access site complications were most common. No significant haemorrhage or graft explant was recorded. The mean follow-up period was 32.4 months (range 1-108 months). Primary patency was 92.9% (95% CI: 83.8-100.0) at 6 months and decreased to 77.7% (95% CI: 63.4-95.2) at 24 months. Sac shrinkage or stability was noted in 17/29 (58.6%). Re-intervention was performed in 9/29 (31%) for limb occlusion (2/9, 22.2%), renal artery stent occlusion (1/9, 11.1%) and endoleaks (6/9, 66.6%). Assisted patency was maintained at 100% for 12 months before decreasing to 66.7% (95% CI: 37.9-100.0) at 24 months. The study reports the first mid-long-term result in this region, though limited by the sample size. Re-intervention at 30% suggests that disease and procedures remain challenging, emphasising the need to assimilate lessons and experience at high-volume centres.

摘要

鉴于开放修复相关的围手术期发病率和死亡率风险较高,胸腹主动脉瘤的血管腔内修复术越来越多地被采用。本研究旨在描述在东南亚一家三级中心接受COOK定制血管内移植物装置治疗的患者的中长期结果。回顾性分析了2012年至2022年接受治疗患者的中长期结果。治疗指征为主动脉直径>5.5 cm、6个月内扩大>5 mm或高危形态。记录了临床、手术、早期至晚期并发症及再次干预的详细情况。终点指标为技术成功率、原发性通畅率和原发性辅助通畅率。回顾了29例连续患者的电子病历(64.4±1.6岁;26/29为男性,占89.6%)。24/29(83%)患者患有高血压,20/29(69%)为吸烟者。平均直径为5.5 cm,大多数患者接受Crawford IV型治疗(19/29,65.5%)。血管内移植物置入成功率为100%。开窗导管插入成功率为109/116(94%)。12/29(41%)患者出现30天死亡率和发病率,其中穿刺部位并发症最为常见。未记录到明显出血或移植物取出情况。平均随访期为32.4个月(范围1 - 108个月)。6个月时原发性通畅率为92.9%(95%CI:83.8 - 100.0),24个月时降至77.7%(95%CI:63.4 - 95.2)。17/29(58.6%)患者出现瘤腔缩小或稳定。9/29(31%)患者因肢体闭塞(2/9,22.2%)、肾动脉支架闭塞(1/9,11.1%)和内漏(6/9,66.6%)进行了再次干预。辅助通畅率在12个月时维持在100%,24个月时降至66.7%(95%CI:37.9 - 100.0)。本研究报告了该地区首个中长期结果,不过受样本量限制。30%的再次干预率表明该疾病和治疗方法仍然具有挑战性,强调需要吸收高容量中心的经验教训。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验